2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-150685
    Topo I/COX-2-IN-1 3031418-84-2 98%
    Topo I/COX-2-IN-1 (1H-30) is a potential Topo I/COX-2 inhibitor. Topo I/COX-2-IN-1 inhibits COX-2 and Topo I with the IC50 value of 0.24 μM and 4.42 μM, respectively. Topo I/COX-2-IN-1 can induce apoptosis and inhibit migration of cancer cells, has anti-cancer activity.
    Topo I/COX-2-IN-1
  • HY-150702
    MAGLi 432 2361575-20-2 98%
    MAGLi 432 is a non-covalent, potent, highly selective, and reversible MAGL inhibitor. MAGLi 432 binds with high affinity to the MAGL active site, with IC50 values of 4.2 nM (human enzyme) and 3.1 nM (mouse enzyme). MAGLi 432 can be used in the research of chronic inflammation, blood–brain barrier dysfunction, neurological disorders such as multiple sclerosis, Alzheimer’s disease and Parkinson’s disease.
    MAGLi 432
  • HY-150721
    COX-2-IN-29 3033545-21-7 98%
    COX-2-IN-29 (Compound 15b) is a selective and orally active COX-2 inhibitor with an IC50 of 0.005 μM.
    COX-2-IN-29
  • HY-150732
    IRAK4-IN-18 3032075-26-3 98%
    IRAK4-IN-18 is a potent interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor with an IC50 value of 15 nM. IRAK4-IN-18 can inhibit LPS-induced IL23 production in THP and DC cells, and stop arthritis development in arthritis rats. IRAK4-IN-18 can be used for researching arthritis disease.
    IRAK4-IN-18
  • HY-150733
    IRAK4-IN-19 3032075-32-1 98%
    IRAK4-IN-19 is a potent interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor with an IC50 value of 4.3 nM. IRAK4-IN-19 can inhibit LPS-induced IL23 production in THP and DC cells, and stop arthritis development in arthritis rats. IRAK4-IN-19 can be used for researching arthritis disease.
    IRAK4-IN-19
  • HY-150740
    ODN 21595
    ODN 21595 is a Guanine-Modified TLR7 and TLR9 inhibitor. ODN 21595 inhibits the release of IFN-α and IL-6 with no cytotoxic. ODN 21595 reduces the expression of CD86 and HLA-DR. ODN 21595 has the potential for the research of systemic lupus erythematosus (SLE).
    ODN 21595
  • HY-150760
    GSK5852 1331942-30-3 98%
    GSK5852 (GSK2485852) is an HCV NS5B polymerase inhibitor, with an IC50 value of 50 nM. GSK5852 displays antiviral activity and inhibits HCV with EC50s of 3.0 nM (genotype 1a, GT1a) and 1.7 nM (GT1b), respectively.
    GSK5852
  • HY-150769
    ZLM-66 3033486-43-7 98%
    ZLM-66 is a potent non-nucleoside reverse transcriptase inhibitor (NNRTIs) with an IC50 of 41 nM for wild-type (WT) HIV-1 reverse transcriptase and an EC50 value of 13 nM for wild-type HIV-1. ZLM-66 is a Doravirine (HY-16767) analogs. ZLM-66 can be used for the research of AIDS.
    ZLM-66
  • HY-150797
    QA-68 98%
    QA-68 (QA-68-ZU81) is an effective PROTAC-class BRD9 degrader. QA-68 can inhibit cell cycle progression and cell colony formation. QA-68 has antiproliferative activity against acute myeloid leukemia (AML) cell lines
    QA-68
  • HY-151139
    LJ-4517 2988849-20-1 98%
    LJ-4517 is a potent A2AAR antagonist, with a Ki of 18.3 nM. LJ-4517 is potent in displacing the binding of [3H]ZM241385 (HY-19532) at WT A2AAR. LJ-4517 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    LJ-4517
  • HY-151173
    XO/COX/LOX-IN-1 2831329-35-0 98%
    XO/COX/LOX-IN-1 is a XO/COX/LOX inhibitor with an IC50 of 3.2 μM against rat XO, 10.83 μM against 5-LOX, 12.67 μM against COX-1, and 8.31 μM against COX-2. XO/COX/LOX-IN-1 binds to the active sites of XO, 5-LOX, COX-1 and COX-2, thereby blocking enzyme activities associated with uric acid, leukotriene, prostaglandin synthesis and inflammatory pathways. XO/COX/LOX-IN-1 can be used in the research of hyperuricemia and inflammation.
    XO/COX/LOX-IN-1
  • HY-151174
    PDE4-IN-12 2901084-32-8 98%
    PDE4-IN-12 is a potent pan-PDE4 inhibitor, with IC50s of 3.5 and 15 nM for PDE4 and PDE7, respectively (SI=2.71 and 4.27, respectively). PDE4-IN-12 shows well tolerated, can be used in study of inflammatory bowel diseases (IBDs).
    PDE4-IN-12
  • HY-151188
    DHU-Se1 98%
    DHU-Se1 is a potent anti-inflammatory agent. DHU-Se1 can stimulate macrophages to release the reactive selenium compound and reduce the expression of cellular inflammatory factors (eg: iNOS and TNF-α). DHU-Se1 alleviate the process of inflammation by blocking the polarization of macrophages from M0 to M1.
    DHU-Se1
  • HY-151204
    PknB-IN-1 1447917-39-6 98%
    PknB-IN-1 (Compound 2) is a protein kinase B (PknB) inhibitor (IC50=14.4 μM). PknB-IN-1 shows anti-mycobacterial activity, can inhibit M. tuberculosis H37Rv strain growth (MIC=6.2 μg/mL).
    PknB-IN-1
  • HY-151205
    Antituberculosis agent-3 369606-71-3 98%
    Antituberculosis agent-3 (Compound 2) is an antituberculosis agent. Antituberculosis agent-3 shows anti-mycobacterial activity, and can inhibit M. tuberculosis H37Rv strain growth (MIC=12.5 μg/mL).
    Antituberculosis agent-3
  • HY-151211
    BTK-IN-16 2883232-92-4 98.93%
    BTK-IN-16 is a dual inhibitor of BTK wild type and C481S mutant of Bruton’s tyrosine kinase (BTK) with IC50s of 5.1 and 4.1 μM. BTK-IN-16 can be used for the research of autoimmune diseases and chronic lymphocytic leukemia.
    BTK-IN-16
  • HY-15123S
    (S)-Flurbiprofen-d3 98%
    (S)-Flurbiprofen-d3 (Esflurbiprofen-d3) is the deuterium labeled (S)-Flurbiprofen. (S)-Flurbiprofen is an active enantiomer of Flurbiprofen, with IC50 values of 0.48 μM and 0.47 μM for COX-1 and COX-2, respectively.
    (S)-Flurbiprofen-d3
  • HY-151285
    JAK-2/3-IN-3 2242031-31-6 98%
    JAK-2-/3-IN-3 (compound ST4j) is a potent JAK2/3 inhibitor with IC50s of 13.00 and 14.86 nM for JAK2 and JAK3, respectively. JAK-2-/3-IN-3 inhibits autophosphorylation of JAK2 and induces apoptosis in a dose- and time-dependent manner. JAK-2-/3-IN-3 can be used in studies of lymph derived diseases and leukemia.
    JAK-2/3-IN-3
  • HY-15128R
    9-cis-Retinoic acid (Standard) 5300-03-8 98%
    9-cis-Retinoic acid (Standard) is the analytical standard of 9-cis-Retinoic acid. This product is intended for research and analytical applications. 9-cis-Retinoic acid (ALRT1057), a vitamin A derivative, is a potent RAR/RXR agonist. 9-cis-Retinoic acid induces apoptosis, regulates cell cycle and has anticancer, anti-inflammatory and neuroprotection activities[1][2][3][4][5].
    9-cis-Retinoic acid (Standard)
  • HY-151337
    Aha1/Hsp90-IN-1 2768265-58-1 98%
    Aha1/Hsp90-IN-1 (Compound 17) is an Aha1/Hsp90 complex inhibitor. Aha1/Hsp90-IN-1 disrupts Aha1/Hsp90 interactions with an IC50 of 3.32 μM. Aha1/Hsp90-IN-1 inhibits tau aggregation.
    Aha1/Hsp90-IN-1
Cat. No. Product Name / Synonyms Application Reactivity